Drug delivery deals reflect biologics progress
This article was originally published in Scrip
Executive Summary
While most drug delivery deal-making traditionally revolves around products that have been launched or specialty products to extend and protect a product's market position, a new study from the Indian consulting and investment advisory firm, MP Advisors, suggests a growing trend for early stage agreements.